Skip to content

d4T/3TC/nevirapine will be preferred option for 3 x 5

Community mobilisation key to success of 3 x 5

India to begin free HIV treatment programme, will treat 100,000 within a year

HIV testing in Africa: will VCT for all do more than ABC approach?

Treatment with HAART reduces liver-related mortality in HIV/HCV coinfected patients

Tipranavir now available for emergency use in UK

Gastrointestinal side-effects lead one in eight to change HAART regimen in first year of treatment

African-Americans, Latinos and gay men bear the brunt of new US HIV infections

HAART can be safely delayed until CD4 cell count falls to 200, provided individuals are adherent